Cardio‐Renal‐Metabolic Outcomes Associated With the Use of GLP‐1 Receptor Agonists After Heart Transplantation
Clinical Transplantation · 2024
DOI: 10.1111/ctr.15401 ↗At a glance
Journal article in Clinical Transplantation, 2024. Written by Elena M Donald and 16 co-authors. Institution: Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA. Major MEDLINE topics: Heart Transplantation, Glucagon-Like Peptide-1 Receptor Agonists. Cited 14 times so far (Crossref); 42 references. The full text is freely available in PubMed Central. Funded by: NHLBI NIH HHS.
Abstract (original language)
Background
The use of glucagon‐like‐peptide 1 receptor agonists (GLP1‐RA) has dramatically increased over the past 5 years for diabetes mellitus type 2 (T2DM) and obesity. These comorbidities are prevalent in adult heart transplant (HT) recipients. However, there are limited data evaluating the efficacy of this drug class in this population. The aim of the current study was to describe cardiometabolic changes in HT recipients prescribed GLP1‐RA at a large‐volume transplant center.
Methods
We retrospectively reviewed all adult HT recipients who received GLP1‐RA after HT for a minimum of 1‐month. Cardiometabolic parameters including body mass index (BMI), lipid panel, hemoglobin A1C, estimated glomerular filtration rate (eGFR), and NT‐proBNP were compared prior to initiation of the drug and at most recent follow‐up. We also evaluated for significant dose adjustments to immunosuppression after drug initiation and adverse effects leading to drug discontinuation.
Results
Seventy‐four patients were included (28% female, 53% White, 20% Hispanic) and followed for a median of 383 days [IQR 209, 613] on a GLP1‐RA. The majority of patients ( n = 56, 76%) were prescribed semaglutide. The most common indication for prescription was T2DM alone ( n = 33, 45%), followed by combined T2DM and obesity ( n = 26, 35%). At most recent follow‐up, mean BMI decreased from 33.3 to 31.5 kg/m 2 ( p < 0.0001), HbA1C from 7.3% to 6.7% ( p = 0.005), LDL from 78.6 to 70.3 mg/dL ( p = 0.018) and basal insulin daily dose from 32.6 to 24.8 units ( p = 0.0002).
Conclusion
HT recipients prescribed GLP1‐RA therapy showed improved glycemic control, weight loss, and cholesterol levels during the study follow‐up period. GLP1‐RA were well tolerated and were rarely associated with changes in immunosuppression dosing.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA.
ORCID profiles: Elena M Donald, Elissa Driggin, Jayant K Raikhelkar, Kevin J Clerkin, Ersilia M DeFilippis
Funding
- NHLBI NIH HHS
Cite
APA
Donald, E. M., Driggin, E., Choe, J., Batra, J., Vargas, F., Lindekens, J., Fried, J. A., Raikhelkar, J. K., Bae, D. J., Oh, K. T., Yuzefpolskaya, M., Colombo, P. C., Latif, F., Sayer, G., Uriel, N., Clerkin, K. J., & DeFilippis, E. M. (2024). Cardio‐Renal‐Metabolic Outcomes Associated With the Use of GLP‐1 Receptor Agonists After Heart Transplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.15401
Vancouver
Donald EM, Driggin E, Choe J, Batra J, Vargas F, Lindekens J, et al. Cardio‐Renal‐Metabolic Outcomes Associated With the Use of GLP‐1 Receptor Agonists After Heart Transplantation. Clinical Transplantation. 2024. doi:10.1111/ctr.15401
BibTeX
@article{Donald2024,
author = {Donald, Elena M and Driggin, Elissa and Choe, Jason and Batra, Jaya and Vargas, Fabian and Lindekens, Jordan and Fried, Justin A and Raikhelkar, Jayant K and Bae, David J and Oh, Kyung T and Yuzefpolskaya, Melana and Colombo, Paolo C and Latif, Farhana and Sayer, Gabriel and Uriel, Nir and Clerkin, Kevin J and DeFilippis, Ersilia M},
title = {Cardio‐Renal‐Metabolic Outcomes Associated With the Use of GLP‐1 Receptor Agonists After Heart Transplantation},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.15401}
}
EUVIMED